---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000062"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T10:04:46.746647+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports Q1 net loss $18.7M; cash $76.1M; SENTI-202 IND on track for 2H 2023

## Summary
- Net loss of $18.7M ($0.42 per share) vs $11.8M loss in Q1 2022; revenue $1.3M.
- Cash, equivalents & short-term investments $76.1M; cash runway expected through at least Q1 2024.
- R&D expense $11.3M (+49% YoY) from increased headcount for preclinical programs.
- SENTI-202 logic-gated CAR-NK on track for IND filing in 2H 2023; new AACR data shown.
- Technology transfer to Alameda cGMP facility started to support clinical-scale manufacturing.

## SEC filing metadata
- accession: 0001854270-23-000062
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/0001854270-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/snti-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000062
- JSON: https://secwatch.observer/filing/0001854270-23-000062.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000062.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $18.7 million, EPS $0.42 per basic and diluted share.
  - Period: the quarter ended March 31, 2023
  - Net income: $18.7 million
  - EPS: $0.42 per basic and diluted share
  - Result: reported results
  source text: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/0001854270-23-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.